Fenwick represented Merck Global Health Innovation Fund (Merck GHI) in its participation in Preventice Solutions’ $137 million Series B financing. The round was led by Vivo Capital with participation from Novo Holdings A/S and existing investors including Merck Global Health Innovation Fund, Boston Scientific and Samsung Catalyst Fund.

Preventice Solutions is a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence. More information can be obtained from Preventice Solutions’ announcement.

The Fenwick transaction team included corporate partner Ian Goldstein and associate Sean Childers, as well as antitrust & trade regulation partner Mark Ostrau.

Login

Don’t have an account yet?

Register